Assenagon Asset Management S.A. purchased a new stake in Harrow Health, Inc. (NASDAQ:HROW – Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 802,450 shares of the company’s stock, valued at approximately $16,980,000. Assenagon Asset Management S.A. owned about 2.68% of Harrow Health at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Marshall Wace LLP increased its stake in shares of Harrow Health by 4.0% in the 3rd quarter. Marshall Wace LLP now owns 26,999 shares of the company’s stock valued at $326,000 after acquiring an additional 1,030 shares during the last quarter. UBS Group AG increased its stake in Harrow Health by 11.2% during the 4th quarter. UBS Group AG now owns 12,718 shares of the company’s stock worth $188,000 after purchasing an additional 1,279 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in Harrow Health during the 4th quarter worth approximately $31,000. Tower Research Capital LLC TRC increased its stake in Harrow Health by 530.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,756 shares of the company’s stock worth $33,000 after purchasing an additional 2,319 shares in the last quarter. Finally, Advisor Group Holdings Inc. increased its stake in Harrow Health by 8.4% during the 4th quarter. Advisor Group Holdings Inc. now owns 30,542 shares of the company’s stock worth $450,000 after purchasing an additional 2,360 shares in the last quarter. 69.76% of the stock is owned by institutional investors.
Harrow Health Stock Up 6.3 %
Shares of HROW opened at $19.04 on Friday. Harrow Health, Inc. has a twelve month low of $6.50 and a twelve month high of $28.25. The company has a 50 day moving average of $21.70 and a 200-day moving average of $18.87. The company has a quick ratio of 2.41, a current ratio of 2.92 and a debt-to-equity ratio of 7.84.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the company. TheStreet raised Harrow Health from a “d” rating to a “c” rating in a research note on Tuesday, April 11th. Lake Street Capital increased their target price on Harrow Health from $24.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, April 17th. B. Riley reissued a “buy” rating on shares of Harrow Health in a research note on Thursday, May 4th. Finally, LADENBURG THALM/SH SH raised their price target on shares of Harrow Health from $27.20 to $32.40 in a research note on Friday, May 12th.
Harrow Health Profile
Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Further Reading
- Five stocks we like better than Harrow Health
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
- SMART Global Holdings Momentum, Room To Move Higher?
Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow Health, Inc. (NASDAQ:HROW – Free Report).
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.
